Literature DB >> 9149678

Tumor recurrence and hypertension persistence after successful pheochromocytoma operation.

P F Plouin1, G Chatellier, I Fofol, P Corvol.   

Abstract

Pheochromocytoma is a catecholamine-secreting tumor and a rare cause of hypertension that is usually curable. However, pheochromocytoma may recur as a benign or malignant tumor, and hypertension may persist after successful surgical intervention. The frequency of and risk indicators for tumor recurrence and hypertension persistence after successful surgical intervention have not been adequately studied. We determined tumoral and blood pressure outcome in 129 patients followed-up from initial pheochromocytoma resection to death or to 1994 (796 patient-years). We assessed several candidate indicators for their predictive value for the risk of tumor recurrence or hypertension persistence. Recurrence was defined as the reappearance of disease after normalization of biochemical tests. Pheochromocytoma caused death or persistent or recurrent disease in 28 patients. Of the 114 with benign tumors at initial operation, pheochromocytoma recurred as a benign or malignant tumor 17 to 194 months after initial operation in 16 cases. Kaplan-Meier estimates of pheochromocytoma-free survival were 92% and 80% at 5 and 10 years, respectively. In the 98 living patients without recurrence, Kaplan-Meier estimates of hypertension-free survival were 74% and 45% at 5 and 10 years. In the Cox model, familial pheochromocytoma and a low ratio of plasma epinephrine to total catecholamines were independently associated with recurrence. Familial hypertension and age were similarly associated with hypertension persistence. After surgery for pheochromocytoma, patients should be followed-up indefinitely, especially those with familial tumors or a low epinephrine secretion. Pheochromocytoma should not unreservedly be considered a surgically remediable cause of hypertension.

Entities:  

Mesh:

Year:  1997        PMID: 9149678     DOI: 10.1161/01.hyp.29.5.1133

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  45 in total

Review 1.  The incremental benefit of functional imaging in pheochromocytoma/paraganglioma: a systematic review.

Authors:  Juan P Brito; Noor Asi; Michael R Gionfriddo; Catalina Norman; Aaron L Leppin; Claudia Zeballos-Palacios; Chaitanya Undavalli; Zhen Wang; Juan P Domecq; Gabriela Prustsky; Tarig A Elraiyah; Larry J Prokop; Victor M Montori; Mohammad Hassan Murad
Journal:  Endocrine       Date:  2015-02-06       Impact factor: 3.633

2.  Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy.

Authors:  Irfan Jawed; Margarita Velarde; Roland Därr; Katherine I Wolf; Karen Adams; Aradhana M Venkatesan; Sanjeeve Balasubramaniam; Marianne S Poruchynsky; James C Reynolds; Karel Pacak; Tito Fojo
Journal:  Cell Mol Neurobiol       Date:  2018-04-05       Impact factor: 5.046

3.  An interesting case of paraganglioma.

Authors:  Azhar Ali Malik; Ali El Houni; Hassan Gulshad; Syed Elsiah; Suhail Al-Salam
Journal:  BMJ Case Rep       Date:  2009-05-25

4.  Partial adrenalectomy minimizes the need for long-term hormone replacement in pediatric patients with pheochromocytoma and von Hippel-Lindau syndrome.

Authors:  Dmitry Volkin; Nitin Yerram; Faisal Ahmed; Dawud Lankford; Angelo Baccala; Gopal N Gupta; Anthony Hoang; Jeffrey Nix; Adam R Metwalli; David M Lang; Gennady Bratslavsky; W Marston Linehan; Peter A Pinto
Journal:  J Pediatr Surg       Date:  2012-11       Impact factor: 2.545

Review 5.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

6.  Phaeochromocytoma: a catecholamine and oxidative stress disorder.

Authors:  K Pacak
Journal:  Endocr Regul       Date:  2011-04

7.  Pheochromocytoma in pregnancy: a case report and review of literature.

Authors:  J George; J Y L Tan
Journal:  Obstet Med       Date:  2010-06-03

Review 8.  Pheochromocytomas and paragangliomas: assessment of malignant potential.

Authors:  Tim I M Korevaar; Ashley B Grossman
Journal:  Endocrine       Date:  2011-10-25       Impact factor: 3.633

Review 9.  Therapeutic goals in patients with pheochromocytoma: a guide to perioperative management.

Authors:  N Azadeh; H Ramakrishna; N L Bhatia; J C Charles; F Mookadam
Journal:  Ir J Med Sci       Date:  2015-12-09       Impact factor: 1.568

10.  Surgically correctable adrenal-dependent hypertension: a report of five cases.

Authors:  F Ofei; R Darko; J Appiah-Kusi; H Aduful; H Baddoo; Y Adu-Gyamfi; Y Tettey; Rk Gyasi; L Aleksenko; Ed Yeboah; Eq Arc-Hampong; Aa Yeboah; E Ogoe
Journal:  Ghana Med J       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.